Neurocrine annual meeting re-elects three directors, approves equity plan and auditor

NEUROCRINE BIOSCIENCES INC

Re-elected Class III directors Kevin C. Gorman, Gary A. Lyons, and Johanna Mercier with over 76M votes each.
Advisory vote on named executive officer compensation approved: 78.99M for, 5.67M against, 0.10M abstentions.
Stockholders approved Amended 2025 Equity Incentive Plan: 79.13M for, 5.57M against, 0.07M abstentions.
Ratified Ernst & Young as independent auditor for FY2026: 83.88M for, 6.17M against.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NEUROCRINE BIOSCIENCES INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions Broker Non-votes 83,880,185 6,170,483 67,957 — The appointment of Ernst & Young LLP was ratified.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NEUROCRINE BIOSCIENCES INC shareholders approved An advisory vote on the compensation paid to the Company's named executive officers at the 2026-05-27 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

An advisory vote on the compensation paid to the Company's named executive officers. Votes For Votes Against Abstentions Broker Non-votes 78,993,894 5,669,155 103,231 5,352,345 The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NEUROCRINE BIOSCIENCES INC shareholders approved Election of three Class III Directors for a term of three years expiring at the 2029 Annual Meeting of Stockholders at the 2026-05-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

Election of three Class III Directors for a term of three years expiring at the 2029 Annual Meeting of Stockholders. Votes For Votes Withheld Broker Non-votes Kevin C. Gorman, Ph.D. 76,228,063 8,538,217 5,352,345 Gary A. Lyons 75,278,705 9,487,575 5,352,345 Johanna Mercier 74,671,942 10,094,338 5,352,345 The three nominees for Class III Director were elected.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NEUROCRINE BIOSCIENCES INC shareholders approved Approval of the Amended 2025 Plan at the 2026-05-27 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

Approval of the Amended 2025 Plan. Votes For Votes Against Abstentions Broker Non-votes 79,131,622 5,568,926 65,732 5,352,345 The Amended 2025 Plan was approved.

View on SEC.gov

Browse all shareholder votes →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-26-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.